tbResList Print — Ash Ashwagandha(Withaferin A)

Description: <p><b>Ashwagandha (Withaferin A)</b> — Withaferin A (WA; WFA) is a bioactive steroidal lactone (a “withanolide”) found in <i>Withania somnifera</i> (ashwagandha/Indian ginseng), with most translational oncology discussion centered on WA as a small-molecule electrophile rather than the whole-herb supplement. It is best classified as a natural-product small molecule (steroidal lactone/withanolide) with pleiotropic proteostasis, cytoskeletal, redox-stress, and inflammatory signaling effects; in supplements, WA exposure depends strongly on extract standardization (root vs leaf, % withanolides) and formulation.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Hsp90-axis disruption (incl. client protein destabilization) leading to proteostasis stress and multi-client oncoprotein depletion</li>
<li>Covalent targeting of intermediate filaments (notably vimentin) with downstream effects on adhesion/migration, EMT programs, and angiogenic endothelium</li>
<li>Pro-oxidative stress signaling in cancer cells with mitochondrial dysfunction, ER stress/UPR engagement, and apoptosis execution</li>
<li>Inflammation and survival signaling suppression (notably NF-κB-centric programs; context-dependent immune modulation)</li>
<li>Contextual transcriptional/epigenetic modulation (e.g., HDAC/DNMT-related signals) contributing to anti-proliferative phenotypes</li>
<li>Metabolic stress signaling (glycolysis/HIF-1α/ATP depletion) as a secondary vulnerability in susceptible models</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> WA shows measurable systemic exposure in animals (reported oral bioavailability in rats), but PK is variable across species, doses, and extract matrices; human exposure data exist from a phase I osteosarcoma study and from healthy-volunteer PK work on standardized <i>Withania</i> extracts measuring circulating withanolides (including WA). WA is lipophilic and subject to first-pass metabolism; typical pharmacodynamic in-vitro micromolar concentrations may exceed achievable unbound plasma levels depending on formulation and dosing.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic cancer studies use ~1–10 µM WA; translation requires caution because free (unbound) systemic concentrations and tumor penetration are not well-constrained in humans, and whole-extract products can have low/variable WA content (model- and formulation-dependent).</p>
<p><b>Clinical evidence status:</b> Limited human oncology evidence: a phase I study in advanced high-grade osteosarcoma reported feasibility/safety and proposed a daily dose level; an active clinical trial evaluates an ashwagandha/withaferin-A strategy with liposomal doxorubicin in recurrent ovarian cancer. Most anticancer support remains preclinical, while non-oncology human data for ashwagandha primarily address stress/sleep and are not evidence of anticancer efficacy.</p>


The main active constituents of Ashwagandha leaves are alkaloids and steroidal lactones (commonly known as Withanolides).<br>
-The main constituents of ashwagandha are withanolides such as withaferin A, alkaloids, steroidal lactones, tropine, and cuscohygrine.<br>
Ashwagandha is an herb that may reduce stress, anxiety, and insomnia.<br>
*-Ashwagandha is often characterized as an antioxidant.<br>
-Some studies suggest that while ashwagandha may protect normal cells from oxidative damage, it can simultaneously stress cancer cells by tipping their redox balance toward cytotoxicity.<br>
Pathways:<br>
-Induction of Apoptosis and ROS Generation<br>
-Hsp90 Inhibition and Proteasomal Degradation<br>

<br>
Cell culture studies vary widely, typically ranging from low micromolar (e.g., 1–10 µM).<br>
In animal models (commonly mice), Withaferin A has been administered in doses ranging from approximately 2 to 10 mg/kg body weight.<br>
- General wellness, Ashwagandha supplements are sometimes taken in doses ranging from 300 mg to 600 mg of an extract (often standardized to contain a certain percentage of withanolides) once or twice daily.<br>
- 400mg of WS extract was given 3X/day to schizophrenia patients. report#2001.<br>
- Ashwagandha Pure 400mg/capsule is available from mcsformulas.com.<br>

<br>
-Note <a href="tbResList.php?qv=36&tsv=1109&wNotes=on&exSp=open">half-life</a> 4-6 hrs?.<br>
<a href="tbResList.php?qv=36&tsv=792&wNotes=on&exSp=open">BioAv</a>
<br>
Pathways:<br>

<!-- ROS : MMP↓, ER Stress↑, Ca+2↑, Cyt‑c↑, Casp3↑, Casp9↑, DNAdam↑, UPR↑, cl-PARP↑-->
- well-recognized for promoting
<a href="tbResList.php?qv=36&tsv=275&wNotes=on">ROS</a> in cancer cells, while no effect(or reduction) on normal cells.<br>
- ROS↑ related:
<a href="tbResList.php?qv=36&tsv=197&wNotes=on&word=MMP↓">MMP↓</a>(ΔΨm),
<a href="tbResList.php?qv=36&tsv=103&wNotes=on">ER Stress↑</a>,
<a href="tbResList.php?qv=36&tsv=459&wNotes=on">UPR↑</a>,
<a href="tbResList.php?qv=36&tsv=356&wNotes=on">GRP78↑</a>,
<!-- <a href="tbResList.php?qv=36&tsv=38&wNotes=on&word=Ca+2↑">Ca+2↑</a>, -->
<a href="tbResList.php?qv=36&tsv=77&wNotes=on">Cyt‑c↑</a>,
<a href="tbResList.php?qv=36&wNotes=on&word=Casp">Caspases↑</a>,
<a href="tbResList.php?qv=36&tsv=82&wNotes=on&word=DNAdam↑">DNA damage↑</a>,
<a href="tbResList.php?qv=36&tsv=239&wNotes=on">cl-PARP↑</a>,
<a href="tbResList.php?qv=36&wNotes=on&word=HSP">HSP↓</a>,
<a href="tbResList.php?qv=36&wNotes=on&word=Prx">Prx</a>,<!-- mitochondrial antioxidant enzyme-->

<br>

<!-- ANTIOXIDANT : NRF2, SOD, GSH, CAT, HO-1, GPx, GPX4, -->
- Confusing results about Lowering AntiOxidant defense in Cancer Cells:
<a href="tbResList.php?qv=36&tsv=226&wNotes=on&word=NRF2↓">NRF2↓</a>,
<a href="tbResList.php?qv=36&word=Trx&wNotes=on">TrxR↓**</a>,<!-- major antioxidant system -->
<a href="tbResList.php?qv=36&tsv=298&wNotes=on&word=SOD↓">SOD↓</a>,
<a href="tbResList.php?qv=36&tsv=137&wNotes=on&word=GSH↓">GSH↓</a>
<a href="tbResList.php?qv=36&tsv=46&wNotes=on">Catalase↓</a>
<a href="tbResList.php?qv=36&tsv=597&wNotes=on">HO1↓</a>
<a href="tbResList.php?qv=36&wNotes=on&word=GPx">GPx↓</a>


<br>




- Raises
<a href="tbResList.php?qv=36&tsv=1103&wNotes=on&word=antiOx↑">AntiOxidant</a>
defense in Normal Cells:
<a href="tbResList.php?qv=36&tsv=275&wNotes=on&word=ROS↓">ROS↓</a>,
<a href="tbResList.php?qv=36&tsv=226&wNotes=on&word=NRF2↑">NRF2↑</a>,
<a href="tbResList.php?qv=36&tsv=298&wNotes=on&word=SOD↑">SOD↑</a>,
<a href="tbResList.php?qv=36&tsv=137&wNotes=on&word=GSH↑">GSH↑</a>,
<a href="tbResList.php?qv=36&tsv=46&wNotes=on&word=Catalase↑">Catalase↑</a>,
<br>

<!-- INFLAMMATION : NF-kB↓, COX2↓, COX2↓ PRO-INFL CYTOKINES: IL-1β↓, TNF-α↓, IL-6↓, IL-8↓, -->
- lowers
<a href="tbResList.php?qv=36&tsv=953&wNotes=on&word=Inflam">Inflammation</a> :
<a href="tbResList.php?qv=36&tsv=214&wNotes=on&word=NF-kB↓">NF-kB↓</a>,
<a href="tbResList.php?qv=36&tsv=66&wNotes=on&word=COX2↓">COX2↓</a>,
<a href="tbResList.php?qv=36&tsv=235&wNotes=on&word=p38↓">p38↓</a>, Pro-Inflammatory Cytokines :
<a href="tbResList.php?qv=36&tsv=908&wNotes=on&word=NLRP3↓">NLRP3↓</a>,
<a href="tbResList.php?qv=36&tsv=978&wNotes=on&word=IL1β↓">IL-1β↓</a>,
<a href="tbResList.php?qv=36&tsv=309&wNotes=on&word=TNF-α↓">TNF-α↓</a>,
<a href="tbResList.php?qv=36&tsv=158&wNotes=on&word=IL6↓">IL-6↓</a>,
<a href="tbResList.php?qv=36&tsv=368&wNotes=on&word=IL8↓">IL-8↓</a>
<br>



<!-- GROWTH/METASTASES : EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1, uPA↓, VEGF↓, ERK↓
inhibiting metastasis-associated proteins such as ROCK1, FAK, (RhoA), NF-κB and u-PA, MMP-1 and MMP-13.-->
- inhibit Growth/Metastases :
<a href="tbResList.php?qv=36&tsv=604&wNotes=on">TumMeta↓</a>,
<a href="tbResList.php?qv=36&tsv=323&wNotes=on">TumCG↓</a>,
<a href="tbResList.php?qv=36&tsv=96&wNotes=on">EMT↓</a>,
<a href="tbResList.php?qv=36&tsv=204&wNotes=on">MMPs↓</a>,
<a href="tbResList.php?qv=36&tsv=201&wNotes=on">MMP2↓</a>,
<a href="tbResList.php?qv=36&tsv=203&wNotes=on">MMP9↓</a>,
<a href="tbResList.php?qv=36&tsv=308&wNotes=on">TIMP2</a>,
<!-- <a href="tbResList.php?qv=36&tsv=415&wNotes=on">IGF-1↓</a>, -->
<a href="tbResList.php?qv=36&tsv=428&wNotes=on">uPA↓</a>,
<a href="tbResList.php?qv=36&tsv=334&wNotes=on">VEGF↓</a>,
<a href="tbResList.php?qv=36&tsv=1284&wNotes=on">ROCK1↓</a>,
<!-- <a href="tbResList.php?qv=36&tsv=110&wNotes=on">FAK↓</a>, -->
<!-- <a href="tbResList.php?qv=36&tsv=273&wNotes=on">RhoA↓</a>, -->
<a href="tbResList.php?qv=36&tsv=214&wNotes=on">NF-κB↓</a>,
<a href="tbResList.php?qv=36&tsv=79&wNotes=on">CXCR4↓</a>,
<a href="tbResList.php?qv=36&tsv=1247&wNotes=on">SDF1↓</a>,
<a href="tbResList.php?qv=36&tsv=304&wNotes=on">TGF-β↓</a>,
<a href="tbResList.php?qv=36&tsv=719&wNotes=on">α-SMA↓</a>,
<a href="tbResList.php?qv=36&tsv=105&wNotes=on">ERK↓</a>
<!-- <a href="tbResList.php?qv=36&tsv=1178&wNotes=on">MARK4↓</a> --> <!-- contributing to tumor growth, invasion, and metastasis-->
<br>

<!-- REACTIVATE GENES : HDAC↓, DNMT1↓, DNMT3A↓, EZH2↓, P53↑, -->
- reactivate genes thereby inhibiting cancer cell growth :
<a href="tbResList.php?qv=36&tsv=140&wNotes=on">HDAC↓</a>(combined with sulfor),
<a href="tbResList.php?qv=36&tsv=85&wNotes=on">DNMT1↓</a>,
<a href="tbResList.php?qv=36&tsv=86&wNotes=on">DNMT3A↓</a>,
<!-- <a href="tbResList.php?qv=36&tsv=108&wNotes=on">EZH2↓</a>, -->
<a href="tbResList.php?qv=36&tsv=236&wNotes=on">P53↑</a>,
<a href="tbResList.php?qv=36&wNotes=on&word=HSP">HSP↓</a>,
<a href="tbResList.php?qv=36&tsv=506&wNotes=on">Sp proteins↓</a>,
<a href="tbResList.php?qv=36&wNotes=on&word=TET">TET↑</a>
<br>

<!-- CELL CYCLE ARREST : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓ -->
- cause Cell cycle arrest :
<a href="tbResList.php?qv=36&tsv=322&wNotes=on">TumCCA↑</a>,
<!-- <a href="tbResList.php?qv=36&tsv=73&wNotes=on">cyclin D1↓</a>, -->
<a href="tbResList.php?qv=36&tsv=378&wNotes=on">cyclin E↓</a>,
<a href="tbResList.php?qv=36&tsv=467&wNotes=on">CDK2↓</a>,
<a href="tbResList.php?qv=36&tsv=894&wNotes=on">CDK4↓</a>,
<!-- <a href="tbResList.php?qv=36&tsv=895&wNotes=on">CDK6↓</a>, -->
<br>

<!-- MIGRATION/INVASION : TumCMig↓, TumCI↓, FAK↓, ERK↓, -->
- inhibits Migration/Invasion :
<a href="tbResList.php?qv=36&tsv=326&wNotes=on">TumCMig↓</a>,
<a href="tbResList.php?qv=36&tsv=324&wNotes=on">TumCI↓</a>,
<a href="tbResList.php?qv=36&tsv=309&wNotes=on&word=TNF-α↓">TNF-α↓</a>, <!-- encourages invasion, proliferation, EMT, and angiogenesis -->
<!-- <a href="tbResList.php?qv=36&tsv=110&wNotes=on">FAK↓</a>, -->
<a href="tbResList.php?qv=36&tsv=105&wNotes=on">ERK↓</a>,
<a href="tbResList.php?qv=36&tsv=96&wNotes=on">EMT↓</a>,
<a href="tbResList.php?qv=36&tsv=1117&wNotes=on">TOP1↓</a>,
<!-- <a href="tbResList.php?qv=36&tsv=657&wNotes=on">TET1↓</a>, -->
<br>

<!-- GLYCOLYSIS : ATP↓, HIF-1α↓, PKM2↓, cMyc↓, PDK1↓, GLUT1↓, LDHA↓, HK2↓, Glucose↓, GlucoseCon↓, lactateProd, OXPHOS -->
- inhibits
<a href="tbResList.php?qv=36&tsv=129&wNotes=on">glycolysis</a>
/<a href="tbResList.php?qv=36&tsv=947&wNotes=on">Warburg Effect</a> and
<a href="tbResList.php?qv=36&tsv=21&wNotes=on&word=ATP↓">ATP depletion</a> :
<a href="tbResList.php?qv=36&tsv=143&wNotes=on">HIF-1α↓</a>,
<a href="tbResList.php?qv=36&tsv=772&wNotes=on">PKM2↓</a>,
<a href="tbResList.php?qv=36&tsv=35&wNotes=on">cMyc↓</a>,
<a href="tbResList.php?qv=36&tsv=566&wNotes=on&word=GLUT">GLUT1↓</a>,
<a href="tbResList.php?qv=36&tsv=906&wNotes=on">LDH↓</a>,
<a href="tbResList.php?qv=36&tsv=175&wNotes=on&word=LDH">LDHA↓</a>,
<a href="tbResList.php?qv=36&tsv=773&wNotes=on">HK2↓</a>,
<!-- <a href="tbResList.php?qv=36&wNotes=on&word=PFK">PFKs↓</a>, -->
<!-- <a href="tbResList.php?qv=36&wNotes=on&word=PDK">PDKs↓</a>, -->
<!-- <a href="tbResList.php?qv=36&tsv=847&wNotes=on">ECAR↓</a>, -->
<a href="tbResList.php?qv=36&tsv=230&wNotes=on">OXPHOS↓</a>,
<a href="tbResList.php?qv=36&tsv=356&wNotes=on">GRP78↑</a>,
<!-- <a href="tbResList.php?qv=36&tsv=1278&wNotes=on">Glucose↓</a>, -->
<a href="tbResList.php?qv=36&tsv=623&wNotes=on">GlucoseCon↓</a>
<br>


<!-- ANGIOGENESIS : VEGF↓, VEGFR2↓, HIF-1α↓, NOTCH↓, FGF↓, PDGF↓, EGFR↓ ITG(Integrins↓)-->
- inhibits
<a href="tbResList.php?qv=36&tsv=447&wNotes=on">angiogenesis↓</a> :
<a href="tbResList.php?qv=36&tsv=334&wNotes=on">VEGF↓</a>,
<a href="tbResList.php?qv=36&tsv=143&wNotes=on">HIF-1α↓</a>,
<a href="tbResList.php?qv=36&wNotes=on&word=NOTCH">Notch↓</a>,
<!-- <a href="tbResList.php?qv=36&wNotes=on&word=FGF">FGF↓</a>, -->
<a href="tbResList.php?qv=36&wNotes=on&word=PDGF">PDGF↓</a>,
<a href="tbResList.php?qv=36&tsv=94&wNotes=on&word=EGFR↓">EGFR↓</a>,
<a href="tbResList.php?qv=36&&wNotes=on&word=ITG">Integrins↓</a>,
<br>

<!-- CSCs : CSC↓, CK2↓, Hh↓, GLi↓, GLi1↓, -->
- inhibits Cancer Stem Cells :
<a href="tbResList.php?qv=36&tsv=795&wNotes=on">CSC↓</a>,
<!-- <a href="tbResList.php?qv=36&tsv=524&wNotes=on">CK2↓</a>, -->
<!-- <a href="tbResList.php?qv=36&tsv=141&wNotes=on">Hh↓</a>, -->
<!-- <a href="tbResList.php?qv=36&tsv=434&wNotes=on">GLi↓</a>, -->
<!-- <a href="tbResList.php?qv=36&tsv=124&wNotes=on">GLi1↓</a>, -->
<!-- <a href="tbResList.php?qv=36&tsv=677&wNotes=on">CD133↓</a>, -->
<!-- <a href="tbResList.php?qv=36&tsv=655&wNotes=on">CD24↓</a>, -->
<a href="tbResList.php?qv=36&tsv=342&wNotes=on">β-catenin↓</a>,
<!--<a href="tbResList.php?qv=36&tsv=357&wNotes=on">n-myc↓</a>, -->
<a href="tbResList.php?qv=36&tsv=656&wNotes=on">sox2↓</a>,
<!--<a href="tbResList.php?qv=36&tsv=222&wNotes=on">notch2↓</a>, -->
<!-- <a href="tbResList.php?qv=36&tsv=1024&wNotes=on">nestin↓</a>, -->
<!-- <a href="tbResList.php?qv=36&tsv=508&wNotes=on">OCT4↓</a>, -->
<br>

<!-- OTHERS : -->
- Others: <a href="tbResList.php?qv=36&tsv=252&wNotes=on">PI3K↓</a>,
<a href="tbResList.php?qv=36&tsv=4&wNotes=on">AKT↓</a>,
<a href="tbResList.php?qv=36&wNotes=on&word=JAK">JAK↓</a>,
<a href="tbResList.php?qv=36&wNotes=on&word=STAT">STAT↓</a>,
<a href="tbResList.php?qv=36&tsv=377&wNotes=on">Wnt↓</a>,
<a href="tbResList.php?qv=36&tsv=342&wNotes=on">β-catenin↓</a>,
<a href="tbResList.php?qv=36&tsv=9&wNotes=on">AMPK</a>,
<a href="tbResList.php?qv=36&tsv=475&wNotes=on">α↓</a>,
<a href="tbResList.php?qv=36&tsv=105&wNotes=on">ERK↓</a>,
<!-- <a href="tbResList.php?qv=36&tsv=1014&wNotes=on">5↓</a>, -->
<a href="tbResList.php?qv=36&tsv=168&wNotes=on">JNK</a>,
<br>


<!-- SYNERGIES : -->
- Synergies:
<a href="tbResList.php?qv=36&tsv=1106&wNotes=on">chemo-sensitization</a>,
<a href="tbResList.php?qv=36&tsv=1171&wNotes=on">chemoProtective</a>,
<a href="tbResList.php?qv=36&tsv=1107&wNotes=on">RadioSensitizer</a>,
<a href="tbResList.php?qv=36&tsv=1185&wNotes=on">RadioProtective</a>,
<a href="tbResList.php?qv=36&tsv=961&esv=2&wNotes=on&exSp=open">Others(review target notes)</a>,
<a href="tbResList.php?qv=36&tsv=1105&wNotes=on">Neuroprotective</a>,
<a href="tbResList.php?qv=36&tsv=557&wNotes=on">Cognitive</a>,
<a href="tbResList.php?qv=36&tsv=1175&wNotes=on">Renoprotection</a>,
<a href="tbResList.php?qv=36&tsv=1179&wNotes=on">Hepatoprotective</a>,
<a href="tbResList.php?&qv=36&tsv=1188&wNotes=on">CardioProtective</a>,

<br>
<br>
<!-- SELECTIVE: -->
- Selectivity:
<a href="tbResList.php?qv=36&tsv=1110&wNotes=on">Cancer Cells vs Normal Cells</a>
<br>
<br>










<h3>Mechanistic pathway map for Ashwagandha (Withaferin A) in cancer biology</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>

<tr>
<td>1</td>
<td>Hsp90 proteostasis axis</td>
<td>Hsp90 functional inhibition → client proteins ↓ (Akt/EGFR/HER2/Raf/Cdk etc.) → growth/survival signaling ↓</td>
<td>Stress-response engagement possible; tolerability is dose/formulation dependent</td>
<td>R</td>
<td>Multi-node oncogenic network destabilization</td>
<td>Often presented as ATP-independent Hsp90 inhibition with downstream proteasomal degradation of clients; mechanistically central because it collapses multiple driver pathways at once.</td>
</tr>

<tr>
<td>2</td>
<td>Vimentin and intermediate filament remodeling</td>
<td>Vimentin function/organization ↓ → migration/invasion ↓, EMT programs ↓ (context-dependent)</td>
<td>Endothelial and stromal cytoskeleton can be affected; may underlie anti-angiogenic activity</td>
<td>P</td>
<td>Anti-motility / anti-metastatic leverage</td>
<td>WA behaves as a reactive small molecule with reported covalent interaction with vimentin; cytoskeletal perturbation can be rapid and not strictly transcription-driven.</td>
</tr>

<tr>
<td>3</td>
<td>Mitochondrial ROS increase</td>
<td>ROS ↑ → ΔΨm ↓, cyt-c ↑, caspase cascade ↑ → apoptosis ↑</td>
<td>Often ROS ↔ or ↓ with antioxidant response ↑ (model-dependent)</td>
<td>P/R</td>
<td>Selective redox toxicity in susceptible tumors</td>
<td>Frequently paired with ER stress/UPR activation; selectivity is commonly framed as “push cancer over its redox limit,” but this is highly dose- and context-dependent.</td>
</tr>

<tr>
<td>4</td>
<td>ER stress and UPR axis</td>
<td>ER stress ↑, UPR ↑ → proteotoxic stress → apoptosis/autophagy shifts (model-dependent)</td>
<td>Adaptive UPR may occur; excessive dosing can stress normal tissues</td>
<td>R</td>
<td>Proteotoxic stress amplification</td>
<td>Mechanistically synergistic with Hsp90 disruption and ROS signaling; can manifest as GRP78/BiP and related markers ↑ in some systems.</td>
</tr>

<tr>
<td>5</td>
<td>NF-κB inflammatory survival signaling</td>
<td>NF-κB ↓ → cytokine/pro-survival programs ↓, invasion-associated signaling ↓</td>
<td>Anti-inflammatory signaling ↓ may be beneficial in some contexts; immune effects can be mixed</td>
<td>G</td>
<td>Survival/inflammation program suppression</td>
<td>Often aligned with COX-2 and inflammasome-related readouts in inflammatory models; oncology relevance is strongest where NF-κB is a core survival node.</td>
</tr>

<tr>
<td>6</td>
<td>EMT and metastasis signaling</td>
<td>EMT ↓, MMPs ↓, uPA ↓, CXCR4/SDF1 axis ↓ (model-dependent)</td>
<td>Wound-healing programs can be affected (context-dependent)</td>
<td>G</td>
<td>Anti-invasive phenotype</td>
<td>Partly downstream of cytoskeletal (vimentin) effects and NF-κB/TGF-β-linked programs; directionality can vary by tumor lineage and assay.</td>
</tr>

<tr>
<td>7</td>
<td>Glycolysis and HIF-1α</td>
<td>HIF-1α ↓, glycolysis flux ↓, ATP ↓ (susceptible models)</td>
<td>Usually ↔ at low exposure; metabolic stress possible at higher exposure</td>
<td>G</td>
<td>Metabolic vulnerability unmasking</td>
<td>Often secondary to upstream stress (ROS/proteostasis) rather than a primary enzymatic inhibitor; interpret as (context-dependent).</td>
</tr>

<tr>
<td>8</td>
<td>Cell cycle checkpoint control</td>
<td>Cell-cycle arrest ↑ (often G2/M reported), CDK/cyclin signaling ↓</td>
<td>Proliferating normal cells may also be sensitive at higher exposure</td>
<td>G</td>
<td>Anti-proliferative enforcement</td>
<td>Common phenotype readout across WA studies; mechanistic “why” may differ by model (proteostasis vs ROS vs mitotic machinery/cytoskeleton).</td>
</tr>

<tr>
<td>9</td>
<td>NRF2 and antioxidant defense</td>
<td>NRF2 ↓ and antioxidant enzymes ↓ reported in some cancer models; sometimes mixed ↔</td>
<td>NRF2 ↑ and antioxidant enzymes ↑ reported in some normal-tissue protection contexts</td>
<td>G</td>
<td>Redox buffering divergence</td>
<td>Highly model-dependent; WA can behave as a stressor that either suppresses or activates NRF2-linked programs depending on timing, dose, and baseline redox state.</td>
</tr>

<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Micromolar in-vitro dosing common; human oncology exposure/target engagement remains sparsely defined</td>
<td>Supplement heterogeneity (WA content), drug-interaction risk, and organ-specific toxicity signals (notably liver; thyroid) constrain use</td>
<td>—</td>
<td>Formulation + PK + safety gating</td>
<td>Human data exist (phase I osteosarcoma; ongoing ovarian combo), but WA is not an approved anticancer drug and standardized products/target engagement biomarkers are not yet mature.</td>
</tr>
</table>

<p><b>TSF legend:</b> P: 0–30 min &nbsp;&nbsp; R: 30 min–3 hr &nbsp;&nbsp; G: &gt;3 hr</p>